Results 151 to 160 of about 11,328,563 (174)
Some of the next articles are maybe not open access.
ISMRM Annual Meeting
Motivation: Using anti-amyloid monoclonal antibodies to treat Alzheimer’s disease (AD) can lead to ‘Amyloid-Related Imaging Abnormalities’ (ARIA), indicative of oedema (ARIA-E). ARIA-E's transient nature poses diagnostic challenges, necessitating efficient detection and monitoring, which is critical for drug development ...
Ela Kanani +10 more
openaire +1 more source
Motivation: Using anti-amyloid monoclonal antibodies to treat Alzheimer’s disease (AD) can lead to ‘Amyloid-Related Imaging Abnormalities’ (ARIA), indicative of oedema (ARIA-E). ARIA-E's transient nature poses diagnostic challenges, necessitating efficient detection and monitoring, which is critical for drug development ...
Ela Kanani +10 more
openaire +1 more source
Amyloid-Related Imaging Abnormalities (ARIA): essential insights for diagnosis and management
Learning objectives: 1. Explain the pathophysiology of ARIA in the context of Alzheimer’s disease and provide a brief overview of monoclonal antibodies used in its treatment. 2.openaire +1 more source
Abstract Amyloid-related imaging abnormality (ARIA) is the most common adverse event associated with amyloid-beta (Aβ) immunotherapy. The neuropathology underlying active ARIA lesions has been studied in only a few rare fatal cases. A faithful translational model of ARIA should allow a better understanding of pathogenic mechanisms and ...
Edward D. Plowey +13 more
openaire +1 more source
Edward D. Plowey +13 more
openaire +1 more source
ISMRM Annual Meeting
Amyloid Related Imaging Abnormality (ARIA) was reported in 40% of patients treated with anti-amyloid beta drugs in phase 3 trials. It is expected to be a significant factor in the clinical application of new Alzheimer’s Disease (AD) modifying therapies and requires standardized and practical imaging.
Sandeep Ganji +5 more
openaire +1 more source
Amyloid Related Imaging Abnormality (ARIA) was reported in 40% of patients treated with anti-amyloid beta drugs in phase 3 trials. It is expected to be a significant factor in the clinical application of new Alzheimer’s Disease (AD) modifying therapies and requires standardized and practical imaging.
Sandeep Ganji +5 more
openaire +1 more source
American Journal of Respiratory and Critical Care Medicine
Abstract Alzheimer's disease is a neurodegenerative disorder which primarily affects older adults and is the most common cause of dementia. Recombinant monoclonal antibody treatments such as Lecanemab are directed against early Alzheimer's disease and are highly effective at reducing amyloid plaque burden, however, are paired with ...
V. Singh +6 more
openaire +1 more source
Abstract Alzheimer's disease is a neurodegenerative disorder which primarily affects older adults and is the most common cause of dementia. Recombinant monoclonal antibody treatments such as Lecanemab are directed against early Alzheimer's disease and are highly effective at reducing amyloid plaque burden, however, are paired with ...
V. Singh +6 more
openaire +1 more source
Stroke
Background: Amyloid-related Imaging Abnormalities (ARIA) are adverse effects that occur during amyloid beta monoclonal antibody treatment for Alzheimer's disease, including edema-type ARIA and hemorrhage-type ARIA. Few retrospective analysis have compared ARIA-H incidence among individual monoclonal antibodies, and a ...
Dinghao An, Yun Xu
openaire +1 more source
Background: Amyloid-related Imaging Abnormalities (ARIA) are adverse effects that occur during amyloid beta monoclonal antibody treatment for Alzheimer's disease, including edema-type ARIA and hemorrhage-type ARIA. Few retrospective analysis have compared ARIA-H incidence among individual monoclonal antibodies, and a ...
Dinghao An, Yun Xu
openaire +1 more source
Amyloid-Related Imaging Abnormalities: An Update
American Journal of Roentgenology, 2023Michelle Roytman, Greg Zaharchuk
exaly